Milestones :: Perspectives :: Research
China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
National Medical Products Administration – PRC [to 6 Mar 2021]
Sinopharm chairman says vaccines can protect against COVID variants
Early research shows that the inactivated COVID-19 vaccines produced by Sinopharm can provide protection against 10 mutated variants of SARS-CoV-2, including strains from the United Kingdom and South Africa, said Yu Qingming, Sinopharm’s board chairman and a deputy to the National People’s Congress.
Output of Sinopharm COVID-19 vaccines to top 1 bln doses in 2021
China has put the inactivated COVID-19 vaccines developed by state-owned pharmaceutical firm Sinopharm into mass production and this year’s output is expected to surpass 1 billion doses, Yu Qingming, chairman of Sinopharm Group, said on March 3.
Over 5 mln get COVID-19 vaccine in Beijing
Over 5 million people in Beijing had received COVID-19 vaccines as of 2 pm on March 2, local authorities said.
New vaccine to ‘provide 2-year protection’
An adenovirus vector vaccine against COVID-19 by CanSino Biologics is projected to provide protection for two years if a booster shot is administered, said a scientist who played a key role in the vaccine’s development.